US Patent Issued to CHANGEN THERAPEUTICS (SHANGHAI) on Sept. 8 for "Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,372, issued on Sept. 8, was assigned to CHANGEN THERAPEUTICS (SHANGHAI) Co. LTD. (Shanghai).

"Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell" was invented by Wei Qiang Gao (Shanghai), Bin Ma (Shanghai) and Pan Yin (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "An immunotherapy method of targeted chemokine and cytokine delivery by a mesenchymal stem cell that expresses an immunostimulatory factor. The immunostimulatory factor is selected from the following group: CCL3, CCL19, CCL21, XCL1, CXCL9, OX40L, 4-1BBL, GITRL, CD40L, or a combination thereof. At a tumor site, the mesenchymal stem cell specif...